President Biden and other world leaders are pushing more dosages to more countries in need and there’s encouraging news from Novavax. Clinical data shows that their newest vaccine could become a big tool in the fight against COVID.
Novavax released data from phase three clinical trials saying its COVID vaccine’s overall efficacy reached 90% and is 100% effective in preventing moderate and severe disease. It even showed 93% efficacy against virus variants which could make the shot a good option for booster doses.
Novavax CEO Stanley Erck said, “The U.S. is going to need booster shots later this year and I think our vaccine will be very useful for that.”
Novavax vials can also be stored in a regular refrigerator, making them more accessible to low-income countries.
Erck said, “The world has to be vaccinated to prevent this, to stop the pandemic, and, and our vaccine is one of the tools in that toolkit.”
With a new vaccine starting to come online, there’s a question of whether you need to match a potential booster shot with your original shot. A study is looking at that right now. Volunteers that have received the big three vaccines are now getting a Moderna booster. Results are not out yet but could be in the next few weeks.
© 2024 KOBI-TV NBC5. All rights reserved unless otherwise stated.